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SUMMARY
Despite the well described infiltration of cells of the cellular immune system in vasculitic lesions
and the granuloma formation in patients with WG, the role of T cell-mediated autoimmunity in
WG is not clear. Reports of T cell proliferation in response to neutrophil azurophilic granule
proteins are contradictory. In this study we have assessed the proliferation of T cells of WG
patients to purified proteinase 3 (PR3) and to total azurophitic granule proteins in two different
assays. In addition to the classical proliferation assay with isolated peripheral blood mononuclear
cells, we have used a whole blood proliferation assay. In both assays we found proliferative
responses to PR3 in patients with WG. The number of patients reacting to the azurophilic granule
extract was higher than the patients reacting to the purified PR3, suggesting that other
autoantigens may also be involved. We have identified epitopes of PR3 that may be potential
targets of class I-restricted T cell responses in the context of HLA-A*0201, the most common
MHC class I molecule. These epitopes were determined by the binding of synthetic PR3 peptides to
HLA-A*0201 on the antigen-processing defective cell line, T2. In addition, T cell lines were
established from tissue biopsies, obtained from WG patients, and assessed for cytolytic reactivity
against T2 cells, preloaded with synthetic PR3 peptides. We conclude that T lymphocytes of WG
patients have increased proiiferative responses to purified PR3 and to a larger extent to non-
fractionated proteins of azurophilic granules of polymorphonuclear neutrophilic leucocytes
(PMN).
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INTRODUCTION
WG is characterized by a systemic necrotizing vasculitis of
small and medium arteries in combination with crescenlic
necrotizing glomenikmephritis and development of granulo-
mas in the upper airways, lungs and kidneys. The most frequent
clinical manifestations are granulomatous lesions of the lower
and upper respiratory tract and a rapidly progressive glomeru-
lonephritis [1,2]. The pathogenesis of WG is largely unknown,
but a mechanism has been suggested for the endothelial cell
damage and vasculitis in WG patients [3-6]. This model
comprises intravascular activation of cytokine-primed neutro-
phils by anti-neutrophil cytoplasmic antibodies (ANCA) fol-
lowed by degranulation of the neutrophil and release of
lysosomal enzymes and reactive oxygen radicals. ANCA are
autoantibodies, found in the circulation of most WG patients,
directed against several constituents of the azurophilic granules
of neutrophils [7]. Based on the fluorescence pattern on
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ethanol-fixed granulocytes, ANCA can be divided in C-ANCA
(cytoplasmic pattern), P-ANCA (perinuclear pattern) and
aspecific ANCA. The most important target antigens are
proteinase 3 (PR3) for C-ANCA and myeloperoxidase
(MPO) for P-ANCA [7], These antigens are expressed on the
surface of cytokine-primed polymorphonuclear neutrophilic
leucocytes (PMN) and are secreted upon cellular degranula-
tion [8,9]. In addition to activating PMN, C-ANCA may
interfere with the enzymatic activity of PR3 and with the
inhibition of PR3 by aj proteinase inhibitor [10]. Although
levels of ANCA in the circulation tend to correlate with disease
activity [7], not all aspects of the pathophysiology of WG can
be attributed to the presence of ANCA. Massive cellular
infiltrates in the renal interstttium, the nasal mucosa and
(peri)vascular tissue of the lung, mainly consist of T cells, B
cells and macrophages [11-14]. Extensive granuloma forma-
tion [14,15j suggests an important role of cell-mediated immune
reactions in the pathogenesis of this disease. Furthermore,
levels of soluble CD25 are elevated in patients with active
WG, suggesting activation of the cellular immune system [16],
Moreover, a correlation was found between the number of T
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lymphocytes in renal interstitium and renal function of patients
with rapid progressive glomerulonephritis [12]. Lymphocyte
proliferation induced by azurophilic granule proteins [13,17] is
still controversial. In other autoimmune diseases, T cell
responses against the target antigens of autoantibodies have
been described, and have also been implicated in the pathogen-
esis of the disease, such as type 1 diabetes, autoimmune
thyroiditis and myasthenia gravis [18-21],
We have investigated the cellular immune response to
purified PR3 using the classical lymphocyte transformation
test (LTT) and an adaptation of a whole-blood proliferation
assay. This whole-blood assay requires only limited quantities
of blood and no in vitro separation of blood cells [22].
Proliferative responses against exogenous antigens are gener-
ally MHC class H-restricted. However, since PR3 is also
synthesized by endothelial cells [23-25], it may be presented
in the context of MHC class Ion endothelial cells and therefore
be a target for autoreactive CD8^ T cells. Cytotoxic T cells
have been implicated in the pathogenesis of several auto-
immune diseases [26-28]. We have identified epitopes on PR3
that fit into the peptide-binding groove of HLA-A*0201 by
determining binding of synthetic PR3 peptides to HLA-A*0201
on the processing-defective T2 cell line [29]. This strategy has
been successful for determining cytotoxic T lymphocyte (CTL)
epitopes on viral peptides and self-antigens that may act as
targets for tumour-directed T cells [30-32], We have attempted
to use the potential epitopes of PR3 to detect PR3-specific
HLA-A*0201-restricted T cells in T cell lines isolated from
biopsies of inflamed tissues of WG patients.
PATIENTS AND METHODS
Materials
Azurophilic granules were prepared by subcellular fractiona-
tion of freshly isolated neutrophils [33] and the granules were
extracted as described by Goldschmeding el al. [34]. PR3 was
isolated from azurophilic granules as described in Leid et al.
[35], Both preparations were enzymatically active as determined
by the cleavage of the synthetic substrate t-Boc-Ala-ONp
(Sigma B5126). Enzymatic activity of PR3 and azurophilic
granule extract was no longer detectable in the presence of
10% normal human serum.
The Q66-9 CTL clone specific for an influenza peptide was
a kind gift of Dr H. Spits (Department of Immunology, Dutch
Cancer Institute, Amsterdam, The Netherlands). Q66-9 is
specific for the peptide GILGFVFTL of the influenza matrix
protein in the context of HLA-A*0201.
The WG patients who were selected for this study
received limited or no immunosuppressive therapy, or had a
stimulation index (SI) higher than 2 in the corresponding
proliferation assay upon stimulation with a recall antigen
(tetanus toxoid (TT)). All patients were positive in the
ANCA fluorescence assay, litres ^ 64. Mean age of the
patients was 52 years (range 28-87 years) and all patients had
histology-proven WG. Healthy laboratory workers were used
as controls.
L
The culture medium was Iscove's modified Dulbecco's
medium supplemented with penicillin/streptomycin, gluta-
mine, 0-mercaptoethanol (IMDM). IMDM containing 10%
pooled human serum (IMDM + ) was used for most cell
cultures.
Lymphocyte transformation test
Peripheral blood mononuclear cells (PBMC) were isolated from
fresh heparinized blood by Ficoll amidotrizoate density separa-
tion. The cells were washed three times with PBS to remove
platelets and washed once with IMDM+. The cells were resus-
pended in JMDM+ to a concentration of l x 106 cells/ml and
100/jl were transferred to each well of 96-well U-bottomed plates
(Costar, Badhoevedorp, The Netherlands). One hundred micro-
litres of PR3 (32^g/ml), Lymphocult T (20%) or phytohaemag-
glutinin (PHA; 2 ̂ g/ml) were added per well. The cells were
incubated in a humidified incubator with 5% CO2 at 37°C for 5
days, and 16 h before harvesting, 3H-thymidine was added (1 fiCi/
well; Amersham, Den Bosch, The Netherlands). Cells were
harvested in a Skatron (Lier, Norway) cell harvester and 3H-
thymidine incorporation was assessed using a LKB scintillation
counter and Packard opti-fluor scintillation fluid. All experiments
were performed in triplicate and background proliferation was
usually less than 2000 ct/min with medium alone. Assays with
higher background proliferation were not included in the results.
Whole-blood proliferation assay
This method was adapted from Bloemena etal. [22]. Hepar-
inized peripheral blood of humans or rats was diluted 1:10 in
IMDM and transferred in 150-^1 volumes per well to a 96-well
flat-bottomed plate (Greiner B.V., Alphen a/d Rijn, The
Netherlands). Fifty microlitres of PR3 (4, 16 or 64 fig/ml) in
IMDM were added per well and as a control 50 /il of Lymfocult
T (40% in IMDM) or rat T cell growth factor (TCGF; 40% in
IMDM) or IMDM alone were added. Incubation and harvest-
ing were performed as described for the LTT. All experiments
were performed in triplicate and background proliferation with
medium alone was usually less than 200 ct/min.
Immunization of the rats with PR3
Five male Wistar rats (180-200 g) were immunized subcuta-
neously with 2011% of PR3 in Freund's complete adjuvant
(FCA). After 14 days the rats were boosted with 20 ̂ g of
PR3 in Freund's incomplete adjuvant (FIA). Venous blood
(1-5 ml) was taken from the tail vein by incision 6 days after
booster immunization. The blood samples were collected in
sterile vials containing 75 U of heparin (Organon Technika,
Boxtel, The Netherlands).
Selection of synthetic peptides of PR3
Nonamer, 10-mer and 11-mer sequences of PR3 were selected
based on the consensus sequences of HLA-A*0201-binding
peptides using two different computer programs. The consen-
sus sequence used by the first program [30) is based on the
sequence of peptides eluted from HLA-A*0201 [36,37]. The
second program uses a consensus sequence based on the
reported binding of synthetic peptides to HLA-A*0201 in vitro
[48]. The peptides finally synthesized were those selected from
the list of peptides generated by both programs. This selection
was based on the rankings of the peptides in the list and on the
hydrophobicity of the peptide. Peptides were synthesized using
Fmoc chemistry on an Abimed AMS 422 automated multiple
peptide synthesizer. Purity of peptides was more than 90% as
determined by reverse-phase high performance liquid chroma-
tography (HPLC) analysis. Extremely hydrophobic peptides
were excluded due to their insolubility. A list of the 28 synthetic
peptides synthesized and tested for in vitro binding to
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Table 1. Overview of the synthesized proteinase 3 (PR3) peptides that

























































































































The maximal fluorescence index (FI) induced by the peptide is
indicated in the fourth column (— indicates FI ^ 0). A + in the last
column indicates that at a concentration of 25 ̂ g/m] or lower an FI of
at least I was induced by the peptide. The (putative) anchor residues are
underlined.
HLA-A*0201 is given in Table 1. The selected peptides were
dissolved in DMSO and diluted to a concentration of 4mg/ml
with PBS and stored in a -80°C freezer. (The concentration of
DMSO never exceeded 0-2% in the final peptide solution.)
Binding of the peptides to HLA-A*0201 was tested in two series
(peptides 1-8 and 9-28).
Assessment of peptide binding to HLA-A*0201 on T2 cells
Binding of the selected peptides to HLA-A*0201 was assessed
as described by Nijman etal. [30]. In short, 174CEM.T2 cells
(T2 cells) were incubated overnight with serial dilutions of the
peptides in IMDM, starting at a concentration of lOOjig/ml,
and the next day the cells were incubated with a MoAb against
HLA-A2 (BB7.2) and subsequently with goat anti-mouse IgG-
FITC (Becton Dickinson, Etten-Leur, The Netherlands). Mean
fluorescence of peptide-incubated T2 cells was compared with
PBS-incubated T2 cells on a FACScan flow cytometer (Becton
Dickinson). The fluorescence index (FI) was calculated for each
concentration of peptide:
(mean fluorescence with peptide - mean background fluorescence)
mean background fluorescence
The maximal FI induced by a peptide and the maximal
dilution of a peptide resulting in an FI higher than 1 were used
as criteria for the binding of a peptide (Table 1). Maximal FI
was usually found at 100^g/ml of peptide, although for some
peptides the FI was maximal at 50 ,ug/ml.
T cell lines from biopsies
Needle biopsies from kidneys and biopsies from lung, skin,
nasal mucosa or salivary gland were cut into very small pieces
and transferred to 24-well culture plates containing 1 ml of
IMDM + /10% Lymphocult T (LcT; Biotest). After 10-14 days
of culture the proliferating T cells were restimulated with
irradiated pooled human lymphocytes and 1 jug/ml of PHA in
1MDM + /10% LcT. After 12 days of culture portions of the T
cells were frozen in liquid nitrogen. The rest of the T cells were
restimulated as described and tested in a cytotoxicity assay
7 days after restimulation.
Cytotoxicity assay
T2 cells (2 x 106) or Epstein-Barr virus (EBV)-transformed B
cells were labelled with 150/iCiof sodium 51chromate for 1 hat
37°C, washed twice with IMDM and resuspended in IMDM+
at a concentration of 4 x 104 cells/ml. Sufficient numbers of
labelled cells were incubated with 20 /ig/ml (final concentration)
of peptide for 15 min at 37CC or without peptide and then
transferred to 96-well plates (2000 cells/well). Various numbers
of T cells were added to the wells, resulting in effector: target
ratios of 100, 50,25 and 12-5 and the plates were centrifuged for
5 min at 1400 rev/rnin. As controls 50 fi\ of IMDM -I- (sponta-
neous release) or 2% Triton X-100 (maximal release) were
added instead of T cells. Supernatant (50 /jl) was harvested
after 4 h of incubation at 37°C and counted in a Packard
gamma counter. The percentage of 51Cr release was calculated
as follows:
ct/min experimental well - ct/min spontaneous release
et/min maximal release — ct/min spontaneous release
Statistical analysis
Student's (-test for paired data was used to calculate P values of
differences between rats before and after immunization. The
upper limit of the normal controls was calculated as follows:
mean SI ± 2 x s.d. Using this limit, P values were calculated by
X2 Fisher's exact test.
RESULTS
To find out whether circulating PR3-specific T cells were
present in WG patients we tested PBMC of 21 patients and
eight healthy controls in an LTT for proliferative responses
against PR3. In the patient group the SI of five patients
exceeded the upper limit of the controls (mean SI±
2 x s.d. = 2'48) and therefore should be considered positive
(Fig. 1). The mean SI of the total patient group in response to
16 fig/ml PR3 was slightly higher than the mean SI of the
controls (mean ± s.d. 1-66 ±0-90 and 1-14 ±0-67, respec-
tively), but these differences were not statistically significant
y = 0-16). Lower concentrations of PR3 resulted in lower
responses in those patients who responded to PR3. No sig-
nificant difference in proliferation was found between patients
with active disease (•) or with non-active disease (O3-
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Patients Controls
Fig. 1. Proliferation of lymphocytes from patients and controls against
]6^ig/ml proteinase 3 (PR3) in a lymphocyte transformation test
(LTT). Proliferation is indicated as stimulation index (SI) (ct/min
with PR3/ct/min with medium alone). The upper limit of the controls
(mean±2 x s.d.) is shown as a dashed line. •, Patients with active
disease.
To test a larger group of patients, an alternative whole-
blood proliferation assay requiring only limited amounts of
blood was used. This assay utilizes non-fractionated peripheral
blood diluted in culture medium, without addition of serum
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Fig. 2. (a) Proliferation of lymphocytes from rats (previously immu-
nized with purified proteinase 3 (PR3)) in a whole blood assay against
various concentrations of PR3 (ct/min). Mean ± s.e.m. of five rats is
indicated, (b) Reactivity of serial dilutions of plasma from rats (pre-
viously immunized with purified PR3) in an ELISA using purified PR3
(OD 405). Corresponding symbols in a and b refer to identical animals.













Patients Controls Patients Controls
Fig. 3. Proliferation of lymphocytes from WG patients and controls
against 16^g/m! proteinase 3 (PR3) or 64^ig/ml of an azurophiïic
granule extract in a whole-blood assay. Proliferation is indicated as
stimulation index (SI; ct/min with PR3/ct/min with medium alone). The
upper limit of the controls (mean ± 2 x s.d.) is shown as a dashed line.
Patients with active disease are represented by filled symbols.
model for the T cell responses to PR3 in rats. We performed
whole-blood assays comparable to the human assay with PR3-
immunized Wistar rats (n = 5). All rats responded to PR3
(Fig. 2a) and a significant proliferation against PR3 was found
with 1, 4 and ló^g/ml PR3 (mean ct/min ± s.d. medium,
109± 10; PR3, 2190±625 and 3892±1054 and 593Ü2048,
respectively, P < 0-05 (paired r-test) for each concentration of
PR3). Some rats responded even to 0-05/jg/ml of PR3 (data not
shown). PR3 seemed to have a slight mitogenic effect at
16 (ig/ml in non-immunized rats, but this was statistically not
significant (ct/min of medium 120± 18; PR3 16/jg/ml, 152±3
(mean ± s.e.m.; P = 0-129). Sera of all rats diluted up to 1:640
were positive in an ELISA using purified PR3 (Fig. 2b).
Having shown the potential use of this assay in rats, we
tested 36 patients and 11 healthy controls in whole-blood
proliferation assays (Fig. 3). Cellular proliferation against
16/ig/ml PR3 and 80/jg/ml of a non-fractionated extract of
azurophiïic granules (granule extract) was tested. Four patients
out of 36 had an SI against PR3 exceeding the upper limit of the
controls (mean +• 2 x s.d. = 1-42 + 2 x 0-58 = 2-58) and were
considered positive. For the whole patient group, differences
in SI between patients and controls were not significant
CP = 0-33).
An almost significant difference between patients and
controls was found for granule extract-induced proliferation
(1-19 ±0-90 and 0-77 ±0-26, respectively (mean ± s.d.), upper
limit of controls = 1-29; P = 0-063). Fourteen patients had an
SI against the granule extract exceeding the upper limit of the
controls. Lower concentrations of antigen generally resulted in
lower responses of those patients who responded to PR3 or the
azurophiïic granule extract. No significant correlation could be
found between the reaction against PR3 and against the
granule extract. However, three of the four patients with
positive response against PR3 also had a positive response
against the granule extract. No significant differences in pro-
liferation between patients with active disease (filled symbols)
and non-active disease (open symbols) were found. Correla-
tions between the responses to PR3 in the LTT and in the
whole-blood assay could not be calculated since patient groups
of both assays were not related and only a few patients were
tested in both assays at the same time.
Since the 95% CI of the mean of the controls (1-03-1-81,




Fig. 4. FACS histograms of the up-regulated HLA-A2 expression
mediated by the indicated peptides (as mentioned in Table 1, + =
positive control, 20 ~ non-binding peptide). Dotted lines indicate the
background fluorescence without peptide. Solid lines indicate the
up-regulated fluorescence mediated by the peptide.
mean = 142) does not equal 1, it can be concluded that PR3
had a slight but significant mitogenic effect (P^Q-05). Simi-
larly, it can be concluded that azurophilic granule extract had a
slight inhibitory effect on the proliferation of control lympho-
cytes (mean SI = 0-77, 95% CI of the mean = 0-61-0-94)
(P<0-05). In this assay, an SI in response to TT of almost 50
could be found in some patients, indicating the efficiency of the
assay. No correlation was found between the responses against
TT and PR3 or granule extract (data not shown).
Since PR3 is synthesized by endothelial cells after stimulation
with tumour necrosis factor-alpha (TNF-a) [24), we investi-
gated whether cytotoxic T cell responses to PR3 in the context
of class I MHC were detectable in T cell lines of WG patients.
Fig. 5. Percentage specific 5lCr-release of 2000 T2 cells at various E:T
ratios induced by a T cell line grown from a lung biopsy of a WG
patient. T2 cells were preincubated either with medium (D) or with
proteinase 3 (PR3) peptides 3 (•), 4 (@), 13 (B), 18 (•) or 23 (B).
We selected and synthesized 28 synthetic peptides of 9-11
amino acids (Table 1), based on two computer models predict-
ing the binding of peptides to HLA-A*0201 ([30], unpublished
results). Actual binding of these peptides to HLA-A*0201 was
tested using the processing-defective T2 cell line. Peptides 3, 4,
13, 18 and 23 induced at least two-fold up-regulation of the
mean fluorescence at concentrations of 25 Mg/ml and higher
(FI > 1). Therefore these peptides are considered to be effec-
tively binding to HLA-A*0201 (Fig. 4). Peptides 9, 1 1, 12 and
16 also induced a maximal FI higher than 1 -0 at concentrations
of 50- 100 fig/mi. This up-regulation was no longer detectable
at concentrations of 25^g/ml and lower, and these peptides
were therefore not used in the cytotoxicity assays (Table I).
Peptides 3, 4, 13, 18 and 23 were used to study the cytotoxic
potential of biopsy-derived T cells of HLA-A*0201 -positive
WG patients. HLA-A2 frequencies are not different in WG
patients compared with the normal population [38-40]. HLA-
A*0201 is the major subtype of A2 and is found at high
frequencies in all human races [41], The presence of HLA-
A*0201 on patient lymphocytes was detected with a cyto-
toxicity assay using EBV-immortalized B cells of HLA-A2-
positive WG patients. After incubation of the B cells with a
HLA-A*0201-binding peptide of the influenza matrix protein,
these cells served as targets for the influenza-specific HLA-
A*0201 -restricted CTL clone Q66-9 [31]. Of the five A2-
positive B cell lines tested, four were HLA-A*0201-positive
and were efficiently lysed by the Q66-9 CTL clone after
incubation with the influenza peptide (data not shown).
Four T cell lines were obtained from biopsies of HLA-
A*0201 -positive patients taken at sites of inflammation (nasal
mucosa, lung, salivary gland and skin). Each cell line was tested
for cytotoxic capacity against 51Cr-labelled T2 cells preincu-
bated with each of the five selected peptides or medium. None
of the peptides induced cytotoxicity higher than the back-
ground lysis of T2 cells preincubated with medium alone. All
T cell lines contained both CD4+ and CD8+ T cells. A
representative experiment is shown (Fig. 5).
DISCUSSION
T cell-mediated autoimmune reactions have been suggested as
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an important factor in the pathogenesis of WG and other
vasculitides, not only because of the influx of T lymphocytes
in inflamed tissues, but also because of the formation of
granulomas in WG patients [14,22]. Secondary evidence for
T cell-mediated inflammatory processes in WG is found in the
enhanced levels of sCD25 in the circulation of patients with
active disease [16]. Although contradictory descriptions of the
proJiferative responses of PBMC of WG patients to PR3 and
other constituents of the azurophilic granules of neutrophils
have been published [17,42], the positive results suggest that T
cell reactivity against target antigens of ANCA could be
important in WG. Furthermore, the predominance of IgG4-
C-ANCA in sera of WG patients suggests repeated stimulation
of PR3-specific B cells by (IL-4-producing) PR3-specific, T
helper cells [43,44].
In the present study, we tested the proliferative capacity of
T cells of WG patients against PR3 and an extract of azur-
ophilic granules from PMN. In a classical proliferation assay
with isolated PBMC we observed that five patients from a panel
of 20 specifically proliferated in the presence of PR3. To test a
larger group of patients we used a modified proliferation assay
that used whole blood instead of isolated PBMC. Using PR3-
immunized rats, it was found that the optimal PR3 concentra-
tion (lo^ig/ml) induced strong proliferative responses in whole
blood of immunized rats without mitogenic effects in non-
immunized animals. Similar results were found with TT in
TT-immunized rats (van Breda-Vriesman, unpublished data).
Using the optima] PR3 concentration we tested a larger group
of patients for PR3-specific proliferation in the whole blood
assay. As in the LIT, a limited group of patients had a
significant proliferative response to 16/jg/ml PR3. Surpris-
ingly, a larger percentage of the patients tested (14/36), reacted
to a non-fractionated azurophilic granule extract. This finding
suggests that other constituents of azurophilic granules may be
targets of autoimmune responses. These antigens may include
myeloperoxidase, cathepsin G and elastase, all of which have
been described as target antigens for ANCA (7]. Our findings
confirm the proliferative response of lymphocytes from WG
patients to azurophilic granule extract, as shown by Rasmussen
& Petersen [13]. Other investigators have not found specific
proliferation of patient lymphocytes using a total cytoplasmic
extract of neutrophüs [17]. This latter finding may reflect the
method of antigen preparation (acid extraction). Another
possible explanation for the higher response to azurophilic
granule extract may be found in the observation that auto-
reactive CD4+ T cell clones from lupus-prone mice specifically
respond to nucleosomes, complexes of DNA and histones,
while purified histones or DNA alone do not stimulate these
clones [45]. The authors suggest that, during processing and
presentation of these complexes, certain epitopes are protected
against proteolysis, whereas these epitopes are degraded during
processing of the purified histones. Similarly, PR3 may be
present in azurophilic granules in the form of multimeres or
complexes with other molecules. During isolation of PR3 these
complexes may be disrupted by the Triton X-100 used for the
extraction of the granules, while the non-fractionated azuro-
philic granule extract used in the proliferation assays is not
treated with detergent.
Another protein that can be a potential target for T cell-
mediated autoimmune responses is a-enolase, a neutrophil
cytosolic protein related to heat shock proteins. Antibodies
against this enzyme have been described in the sera of both WG
and systemic lupus erythematosus (SLE) patients with renal
involvement [46]. T cell responses to heat shock proteins have
been described in various autoimmune diseases, such as rheu-
matoid arthritis [47].
Since PR3 is synthesized by cytokine-activated endothelial
cells, PR3 peptides may be presented in the context of MHC
class I and thus be a target for autoreactive cytotoxic T cells.
We have identified several peptides of PR3 that may be
presented in the context of the common MHC class I molecule
HLA-A*0201. The programs used to select the peptides to be
synthesized and tested for binding to HLA-A*0201 were either
based on the sequences found in peptides eluted from HLA-
A*020I [31,36] or derived from the consensus sequence of an
extended set of synthetic peptides known to bind to HLA-
A*0201 in vitro [48], Peptides 4, 13 and 18 all fulfilled the motif
defined by Rammensee [31] (leucine or isoleucine at position 2
and valine or isoleucine at position 9 or 10), while peptide 4 was
strongly selected by both programs. Peptide 3 has the correct
anchor residues, but the other residues do not match with the
residues found in naturally processed peptides, and therefore
peptide 3 was not selected by the first program. Peptide 23
(FVLTAAHCL) has valine as anchor on position 2, which is
not found in naturally processed peptides on HLA-A*0201
[36]. However, valine at position 2 is incorporated in the
consensus sequence used by the second program, as it supports
in vitro binding of synthetic peptides to HLA-A*0201.
Although it is not clear whether such peptides are processed
naturally, synthetic peptides of the human papillomavirus type
16 (HPV-16) oncogenes E6-E7, selected by binding to class I,
can be effective for the induction of peptide-specific CTL, that
lyse tumour cells in vitro [49]. Attempts to detect CTL activity
against the HLA-A*0201-binding PR3 peptides in T cell lines
derived from biopsies of WG patients were uniformly unsuc-
cessful. This failure might be due to the low frequencies of
peptide-specific CTL in the biopsy tissue or to the culture
conditions that do not favour outgrowth of CTL. It may be
necessary to add IL-12, a potent stimulator of the cellular
immune response [50], to generate T cell lines with higher
frequencies of PR3-specific CTL. Attempts to generate PR3
peptide-specific T cell clones out of biopsy T cell lines, using
peptide-loaded autologous EBV-transformed B cells as stimu-
lator cells, were not successful either. Generation of peptide-
specific T cell lines from peripheral blood of WG patients by
stimulation with peptide-loaded T2 cells (as described pre-
viously [31]) may provide a different way to detect the presence
ofPR3-specificCTL.
Not much is known about the activation of autoreactive
T cells in autoimmunity. In chronic active hepatitis it was
found that liver-derived T cell clones of both the CD4 and
CDS subset are stimulated by class II or class I matched
hepatocytes, respectively, but not by autologous PBMC
[51]. This suggests that autoantigens produced by hepatocytes
are presented not only in the context of class i but also
in the context of class II. This presentation is confirmed by
studies that show that cytosolic proteins can be presented in
the context of class II [52]. Since PR3 is synthesized by
human endothelial cells and murine endothelial cells are
capable of processing and presenting exogenous antigens to T
cells in the context of class II after stimulation with interferon-
gamma (IFN-7) [53], it seems possible that CD4+ and CD8 +
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PR3-specific T cells could be activated by vascular endothelial
cells.
Endothelial cells presenting PR3 peptides in the context of
class I or class II molecules may also be a direct target of
cytotoxic activity of either CDS + orCD4+ autoreactive T cells.
It has been described that hepatocyte-specific T cells of both the
CD4 and the CDS phenotype possess cytotoxic capacity [51].
Cytotoxic autoreactive T cells have been described in type 1
diabetes mellitus [54] and CTL specific for autologous biliary
epithelial cells have been described in primary biliary cirrhosis
patients [28J.
In conclusion, we have demonstrated that PR3-specific T
cells are present in the circulation of some WG patients.
Furthermore, the proliferation to azurophilic granule extract
suggests that T cell recognition of other azurophilic granule
proteins occurs. T cell lines and clones against PR3 or other
granule antigens are needed for further analysis of both the
cytokine pattern and fine specificity of autoreactive T cells in
WG. Furthermore, PR3 induces strong proliferative responses
in whole blood assays using blood of PR3-immunized rats. We
conclude that this whole blood assay is suitable for the long-
itudinal study of cellular (auto)immune responses in laboratory
animals, and it may therefore serve as a potent tool for the
study of animal models of vasculitis or glomerulonephritis.
ACKNOWLEDGMENTS
This study was sponsored by the Netherlands Organization for
Scientific Research. We would like to thank Professor Dr R. Wes
Leid for critically reading this manuscript.
REFERENCES
1 Wegener F. Uber eine eigenartige rhinogene Gramilomatose mit
besonderer Beteiligung des Arteriensystem und der Nieren. Beitr
Pathol Anat 1939; 102:36.
2 Godman GC, Churg J. Wegener's granulomatosis: pathology and
review of the literature. Arch Pathol 1954; 58:533.
3 Keogan MT, Esnault VL, Green AJ, Lockwood CM, Brown DL.
Activation of normal neutrophils by anti-neutrophil cytoplasm
antibodies. Clin Exp Imrnunol 1992; 90:228-34.
4 Charles LA, Caldas ML, Falk RJ, Terrell RS, Jennette JC. Anti-
bodies against granule proteins activate neutrophils in vitro. J
Leukoc Biol 1991; 56:539-46.
5 Eweit BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies
stimulate neutrophils to damage human endothelial cells. Kidney
Int 1992; 41:375-83.
6 Savage CO, Pottinger BE, Gaskin G, Pusey CD, Pearson JD.
Autoantibodies developing to myeloperoxidase and proteinase 3
in systemic vasculitis stimulate neutrophil cytotoxicity toward
cultured endothelial cells. Am J Pathol 1992; 141:335-42.
7 Hagen EC, Ballieux BEPB, van Es LA, Daha MR, van der Woude
FJ. Anti-neutrophil cytoplasmic autoantibodies (ANCA). A review
of the antigens involved, the assays, the clinical and possible
pathogenetic consequences. Blood 1993; 81:1996.
8 Mulder AHL, Heeringa P, Brouwer E, Limburg PC, Kallenberg
CGM. Activation of granulocytes by anti-neutrophil cytoplasmic
antibodies: a Fc-gamma-RII-dependent process. Clin Exp Immunol
1994; 98:270-8.
9 Ludemann J, Utecht B, Gross WL. Detection and quantitation of
anti-neutrophil cytoplasm antibodies in wegener's granulomatosis
by ELISA using affinity-purified antigen. J Imrnunol Methods 1988;
114:167-74.
10 van de Wiel BA, Dolman KM, van der Meer-Gerritsen CH, Hack
CE, von dem Borne AEGK, Goldschmeding R. Interference of
Wegener's granulomatosis autoantibodies with neutrophil pro-
teinase-3 activity. Clin Exp Immunol 1992; 90:409-14.
11 Bolton WK, Innes DJ, Sturgill BC, Kaiser DL. T cells and
macrophages in rapidly progressive glomerulonephritis: clinico-
pathologic correlations. Kidney Int 1987; 32:869-76.
12 Hooke DH, Gee DC, Atkins RC. Leukocyte analysis using mono-
clonal antibodies in human glomeruio-nephritis. Kidney Int 1987;
31:961-72.
13 Rasmussen N, Petersen J. Cellular immune responses and pathogen-
esis in c-ANCA positive vasculitides. J Autoimmun 1993; 6:227-36.
14 Gephardt GN, Ahmad M, Tubbs RR. Pulmonary vasculitis
(Wegener's granulomatosis) immunohistochemical study of T and
B cell markers. Am J Med 1983; 74:700-4.
15 Churg J. Nomenclature of vasculitic syndromes: a historical per-
spective. Am J Kidney Dis 1991; 18:148-53.
16 Stegeman CA, Cohen Tervaert JW, Huitema MG, Kallenberg
CGM. Serum markers of T cell activation in relapses of Wegener's
granulomatosis. Clin Exp Immunol 1993; 91:415-20.
17 Mathieson PW, Lockwood CM, Oliveira DB. T and B cell responses
to neutrophil cytoplasmic antigens in systemic vasculitis. Clin
Immunol Immunopathol 1992; 63:135-41.
18 Roep BO, Kalian AK, Hazenbos WL eial. T cell reactivity to a
38kDa insulin-secretory-granule protein in patients with recent-
onset type 1 diabetes. Lancet 1991; 337:1439-41.
19 Ewins DL, Barnett PS, Ratanachaiyavong S etal. Antigen-specific
T cel! recognition of affinity-purified and recombinant thyroid
peroxidase in autoimmune thyroid disease. Clin Exp Immunol
1992; 98:93-98.
20 Champion BR, Page KR, Parish N et al. Identification of a
thyroxine-containing self-epitope of thyroglobulin which triggers
thyroid autoreactive T cells. J Exp Med 1991; 174:363-70.
21 Berrih-Aknin B, Cohen-Kaminsky S, Lepage V, Neumann D, Bach
JF, Fuchs S. T-cell antigenic sites involved in myasthenia gravis:
correlations with antibody titre and disease severity. J Autoimmun
1991; 4:137-53.
22 Bloemena E, Roos MTL, Van Heijst JLAM, Vossen JMJJ,
Schellekens PTA. Whole-blood lymphocyte cultures. J Immunol
Methods 1989; 1224:161-7.
23 Mayet WJ, Meyer zum Büschenfelde KH. Membrane expression of
proteinase 3 in human endothelial cells under the influence of
different cytokines. Clin Exp Immunol 1993; 93 (sl):17 (Abstr.).
24 Mayet WJ, Csernok E, Szymkowiak C, Gross WL, Meyer zum
Büschenfelde KH. Human endothelial cells express proteinase 3, the
target antigen of anticytoplasmic antibodies in Wegener's granulo-
matosis. Blood 1993; 82:1221-9.
25 Mayet WJ, Hermann EM, Csernok E, Gross WL, Meyer zum
Büschenfelde KH. In vitro interactions of c-ANCA (antibodies to
proteinase 3) with human endotheiïal cells. Adv Exp Med Biol 1993;
336:109-13.
26 Hashimoto E, Lindor KD, Homburger HA elai. Immunohisto-
chemicai characterization of hepatic lymphocytes in primary biliary
cirrhosis in comparison with primary sclerosing cholangitis and
autoimmune chronic active hepatitis [see comments]. Mayo Clin
Proc 1993; 68:1049-55.
27 Itoh N, Hanafusa T, Miyazaki A el at. Mononuclear cell infiltration
and its relation to the expression of major histocompatibility
complex antigens and adhesion molecules in pancreas biopsy
specimens from newly diagnosed insulin-dependent diabetes
mellitus patients. J Clin Invest 1993; 92:2313-22.
28 Onishi S, Satbara T, Nakata S etal. Cytotoxic activity of spleen-
derived T lymphocytes against autologous biliary epithelial cells in
autopsy patients with primary biliary cirrhosis. Liver 1993; 13:
188-92.
29 Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing
mutant-cell contain signal sequence-derived peptides. Nature 1992;
356:443-6.
Cell-mediated autoimmunity in WG patients 193
30 Nijman HW, Houbiers JGA, Vicrboom MPM elal Identification
of peptide sequences that potentially trigger HLA-A2.1 restricted
cytotoric T lymphocytes. Eur J Immunol 1993; 23:1215-9.
31 Nijman HW, Van der Burg SH, Vierboom MPM, Houbiers JGA,
Kast WM, Melief CJM. p53, a potential target for tumor-directed T
cells. Immunoi Letters 1994; 40:171-8.
32 Kast WM, Brandt RM, Drijfhout JW, Melief CJM. Human
leukocyte antigen-A2.1 restricted candidate cytotoxic T lympho-
cyte epitopes of human papillomaviras type 16 E6 and E7 proteins
identified by using the processing-defective human cell line T2. J
Immunother 1993; 14:115-20.
33 Borregaard N, Heiple JM, Simons ER, Clark RA. Subcellular
localization of the b-cytochrome component of the human neutro-
phil microbicidal oxidase: translocation during activation. J Cell
Biol 1983; 97:52-61.
34 Goldschmeding R, van der Schoot CE, ten Sokkel Huinink D et al.
Wegener's granulomatosis autoantibodies identify a novel diisopro-
pylfiuorophosphate-binding protein in the lysosomes of normal
human neutrophils. J Clin Invest 1989; 84:1577-87.
35 Leid RWes, Van der Heijden I, Ballieux BEPB el al. Cleavage and
inacüvaüon of human Cl-inhibitor by the human ïeukocyte pro-
teinase, proteinase-3. Eur J Immunol 1993; 23:2939-45.
36 Rammensee HG, Falk K, Rötzschke O. Pcptides naturally presented
by MHC class I molecules. Ann Rev Immunol 1993; 11:213̂ 14.
37 Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee HG.
Allele-specific motifs revealed by sequencing of self-peptides eluted
from MHC molecules. Nature 1991; 351:290-6.
38 Katz BP, Ailing DW, Hayncs BF, Fauci AS. Association of
Wegener's granulomatosis with HLA-B8. Clin Immunol Immuno-
pathol 1979; 14:268-70.
39 Papiha SS, Murty GE, Ad Hia A, Mains BT, Yenning M. Associa-
tion of Wegener's granulomatosis with HLA antigens and other
genetic markers. Ann Rheum Dis 1992; 51:246-8.
40 Murty GE, Mains BT, Middleton D, Maxwell AP, Savage DA. Hla
antigen frequencies and Wegener's granulomatosis. Clin Otolaryn-
gol 1991; 16:448-51.
41 The databook of the llth International Histocompatibility Work-
shop (Yokohama, Japan) 1991; 2:807.
42 Petersen J, Rasmussen N, Szpirt W, Hermann E, Mayet WJ. T
lymphocyte proliferation to neutrophil cytoplasmic antigen(s) in
Wegener's granulomatosis (WG). Am J KJdney Dis 1991; 18:205
(Abstr.).
43 Brouwer E, Cohen Tervaert JW, Horst G elal. Predominance of
IgGl and IgG4 subclasses of anti-neutrophil cytoplasmic autoanti-
bodies (ANCA) b patients with Wegener's granulomatosis and
clinically related disorders. Clin Exp Immunol 1991; 83:379-86.
44 Spiegelberg HL. Biological role of different antibody classes. In!
Arch Allergy Appl Immunol 1990; 90:22.
45 Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major
immunogen for pathogenic autoantibody-inducing T cells of lupus.
J Exp Med 1993; 177:1367-81.
46 Moodie FDL, Leaker B, Cambridge G, Totty NF, Segal AW.
Aipha-enolasea novel cytosolic autoantigen in ANCA positive
vasculitis. Kidney Int 1993; 43:675-81.
47 Res PCM, Breedveld FC, van Embden JDA etal. Synovial fluid T
cell reactivity against 65 kD heat shock protein of mycobacteria in
early chronic arthritis. Lancet 1988; U:478-80.
48 Dryfhout JW, Brandt RMP, D'Amaro J, Kast WM, Melief CJM.
Detailed motifs for peptide binding to HLA-'0201, derived from
large random sets of peptides using a cellular binding assay. Hum
Immunol 1995; (in press).
49 Feltkamp MCW, Smits HL, Vierboom MPM etal. Vacci-
nation with cytotoxic T lymphocyte epitope-containing peptide
protects against a tumor induced by human papillomavirus type
lo-transformed cells. Eur J Immunol 1993; 23:2242-9.
50 Clerici M, Lucey DR, Berzofsky JA etal. Restoration of HIV-
specific cell-mediated immune responses by interleukin-12 in vitro.
Science 1993:2611721-4.
51 Franco A, Barnaba V, Ruberti G, Benvenuto R, Balsano C, Musea
A. Liver-derived T cell clones in autoimmune chronic active
hepatitis: accessory cell function of hepatocytes expressing class II
major histocompatibiiity complex molecules. Clin Immunoi Immu-
nopathol 1990; 54:382-94.
52 Malnati MS, Marti M, LaVaute T etal. Processing pathways for
presentation of cytosolic antigen to MHC class II-restricted T cells.
Nature 1992; 357:702-4.
53 St. Louis JD, Lederer JA, Lichtman AH. Costimulatory deficient
antigen presentation by an endothelial cell line induces non-
proliferative T cell activation response without anergy. J Exp Med
1993; 178:1597-605.
54 Roep BO, Kalian AK, De Vries RRP. b-Cell antigen-specific lysis of
macrophages by CD4 T-ce!l clones from newly diagnosed IDDM
patient. Diabetes 1992; 41:1380-4.
